基于β-基托桑和 styrene 共聚合物衍生物的功能化纳米颗粒用于donepezil的输送
Fahima M Helaly1, Ahmed A F Soliman2, Eman AboBakr Ali1
1Polymers and Pigments Department, Chemical Industries Research Institute, National Research Centre (Scopus Affiliation ID 60014618), Dokki, Giza, 12622 Egypt.
3 Biotech
|August 28, 2025
概括
这项研究引入了新型的多电解质复合纳米凝,以有效地输送神经治疗中至关重要的药物 - - 登佩西尔. 开发的纳米凝显示持续的药物释放和增强的乙胆酶抑制,为改进治疗铺平了道路.
科学领域:
- 生物材料科学
- 纳米技术
- 药理学
背景情况:
- 通过血脑屏障进行有效的药物输送对于治疗神经疾病至关重要.
- 目前的治疗方法在达到大脑中足够的药物度方面面临挑战.
- 多尼佩西尔是阿尔茨海默病的关键治疗药物,但其治疗能力有限.
研究的目的:
- 开发一种新型的多电解质复合物 (PEC) 纳米凝系统,用于增强多尼的药物输送.
- 研究PEC纳米凝的结构特征和药物封装效率.
- 评估含药纳米凝的体外持续药物释放和乙胆酶 (AChE) 抑制活性.
主要方法:
- 制备硫化-氨酸无水化物 (S-SMA) 并与β-素 (CS) 复合形成PEC纳米粒子.
- 使用传输电子显微镜 (TEM) 等技术对纳米粒子大小,表面电荷和形态的描述.
- 将多尼佩西尔化物 (DH) 封装成优化的CS- S3纳米凝配方 (CS- S3- DH),并评估体外药物释放动力学和ACH抑制.
主要成果:
- 可调节的纳米粒子大小和表面电荷通过PEC中的S-SMA含量变化来实现.
- CS-S3-DH纳米颗粒的平均直径为111 ± 0.4纳米,成功封装了多尼化.
- 与空白纳米凝 (16. 5%) 相比,CS- S3- DH在72小时内持续释放DH,并显著增强ACHE抑制.
结论:
- 开发的β-素/硫化-基无水化PEC纳米凝代表了有效的多尼佩西尔输送的有希望的平台.
- 通过提高药物的生物可用性和有效性,纳米凝系统显示出改善神经疾病治疗结果的潜力.
- 对体内性能和血脑屏障透的进一步研究是有必要的.
相关概念视频
01:26Neurochemical Transmission: Sites of Drug Action
3.5K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.5K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160